Gareth Morgan, PhD is a Research Assistant Professor at the Chobanian and Avedisian School of Medicine. His research focuses on the molecular mechanisms of AL amyloidosis with the aim of developing new treatments for this disease.
Diversity, Equity, Inclusion and Accessibility
Doing science well is challenging because the questions that we ask are difficult. Otherwise, why would we bother? To be successful, researchers need a working environment where their ability to focus on scientific questions is not hindered by arbitrary barriers.
As a scientist and mentor, my role is to direct and facilitate the work carried out by my colleagues and to support their professional development. Science thrives where diverse viewpoints and perspectives are brought to bear on a problem, and everyone has the potential to develop their ability to design, execute and analyze experiments.
We strive to create a welcoming, supportive environment where individuals’ needs are addressed and anyone with an enquiring mind and willingness to learn is able to work to the limits of their own ability. We will endeavor to support colleagues with whatever accommodations they need to achieve their goals. Anyone with an interest in amyloidosis is welcome to join the lab, regardless of age, race, ethnicity, beliefs, sexual or gender orientation, disability or other factors. In turn, we expect a high standard of professionalism and support for other team members and the broader community.
Member
Boston University
BU-BMC Cancer Center
Member
Boston University
Amyloidosis Center
Member
Boston University
Genome Science Institute
Graduate Faculty (Primary Mentor of Grad Students)
Boston University Chobanian & Avedisian School of Medicine, Graduate Medical Sciences
This tab shows grant data from BMC Sponsored Research. It includes:
- Grant title
- Project period and this person’s role on the grant
- PI name, if this person is not the PI (the name will link if PI has a BU Profile)
- Funding source(s). An arrow indicates the flow of funding if multiple sponsors.
- Some grants will show an agency award/project number, and may be a link.
- Data is sorted by project end date, and updated monthly.
This tab shows grant data from BU Sponsored Research. It includes:
- Grant title
- Project period and this person’s role on the grant
- PI name, if this person is not the PI (the name will link if PI has a BU Profile)
- Funding source(s). An arrow indicates the flow of funding if multiple sponsors.
- Some grants will show an agency award/project number, and may be a link.
- Data is sorted by project end date, and updated monthly.
This tab shows grant data that did not automatically get imported into Profiles
from BU or BMC sources.
- Grant title
- Project period and this person’s role on the grant
- PI name, if this person is not the PI (the name will link if PI has a BU Profile)
- Funding source(s). An arrow indicates the flow of funding if multiple sponsors.
- Some grants will show an agency award/project number, and may be a link.
- Data is sorted by project end date, and updated monthly.
This tab shows grant data from the Boston VA. We are only showing grant title, and only for people in the role of PI.
Establishing Strategies to Ameliorate Amyloid Pathology in Light Chain Amyloidosis07/01/2020 - 06/30/2024 (Subcontract PI)
The Scripps Research Institute NIH NIDDK5R01 DK107604-07
Improving Detection of AL Amyloidosis (IDEA) QuickFire Challenge01/01/2022 - 12/31/2023 (PI)
Johnson & Johnson
|
Yr
|
Title
|
Project-Sub Proj
|
Pubs
|
Publications listed below are automatically derived from MEDLINE/PubMed and other
sources, which might result in incorrect or missing publications. Faculty can
login
to make corrections and additions.
-
Maura F, Kaddoura M, Poos AM, Baughn LB, Ziccheddu B, Bärtsch MA, Cirrincione A, Maclachlan K, Chojnacka M, Diamond B, Papadimitriou M, Blaney P, John L, Reichert P, Huhn S, Gagler D, Zhang Y, Dogan A, Lesokhin AM, Davies F, Goldschmidt H, Fenk R, Weisel KC, Mai EK, Korde N, Morgan GJ, Rajkumar SV, Kumar S, Usmani S, Landgren O, Raab MS, Weinhold N. Temporal Genomic Dynamics Shape Clinical Trajectory in Multiple Myeloma. bioRxiv. 2024 Sep 04. PMID: 39282268; DOI: 10.1101/2024.08.30.610457;
-
Leach BI, Ferguson JA, Morgan G, Sun X, Kroon G, Oyen D, Dyson HJ, Wright PE. Conformational Dynamics of an Amyloidogenic Intermediate of Transthyretin: Implications for Structural Remodeling and Amyloid Formation. J Mol Biol. 2024 Aug 15; 436(16):168673. PMID: 38909653; DOI: 10.1016/j.jmb.2024.168673;
-
Soszyn N, Schweigert J, Franco SR, Morgan GJ, Mitchell M, Zablah JE. Computed Tomography-Derived Normative Values of Right Ventricular Outflow Tract Structures in the Pediatric Population. Pediatr Cardiol. 2024 Mar 19. PMID: 38502199
-
Edwards CV, Ferri GM, Villegas-Galaviz J, Ghosh S, Bawa PS, Wang F, Klimtchuk E, Ajayi TB, Morgan GJ, Prokaeva T, Staron A, Ruberg FL, Sanchorawala V, Giadone RM, Murphy GJ. Abnormal global longitudinal strain and reduced serum inflammatory markers in cardiac AL amyloidosis patients without significant amyloid fibril deposition. bioRxiv. 2024 Mar 16.View Related Profiles. PMID: 38558967; DOI: 10.1101/2024.03.14.584987;
-
Wong S, West ME, Morgan GJ. Kinetic evidence for multiple aggregation pathways in antibody light chain variable domains. Protein Sci. 2024 Mar; 33(3):e4871. PMID: 38100259; DOI: 10.1002/pro.4871;
-
Gareth J. Morgan. Understanding and Overcoming Biochemical Diversity in AL Amyloidosis. Israel Journal of Chemistry. 2023; e202300128. View Publication
-
Yan NL, Morgan GJ, Petrassi HM, Wilson IA, Kelly JW. Pharmacological stabilization of the native state of full-length immunoglobulin light chains to treat light chain amyloidosis. Curr Opin Chem Biol. 2023 Aug; 75:102319. PMID: 37279624; DOI: 10.1016/j.cbpa.2023.102319;
-
Nau A, Shen Y, Sanchorawala V, Prokaeva T, Morgan GJ. Complete variable domain sequences of monoclonal antibody light chains identified from untargeted RNA sequencing data. Front Immunol. 2023; 14:1167235.View Related Profiles. PMID: 37143670; DOI: 10.3389/fimmu.2023.1167235;
-
Yan NL, Nair R, Chu A, Wilson IA, Johnson KA, Morgan GJ, Kelly JW. Amyloidogenic immunoglobulin light chain kinetic stabilizers comprising a simple urea linker module reveal a novel binding sub-site. Bioorg Med Chem Lett. 2022 03 15; 60:128571. PMID: 35065233; DOI: 10.1016/j.bmcl.2022.128571;
-
Morgan GJ. Transient disorder along pathways to amyloid. Biophys Chem. 2022 02; 281:106711. PMID: 34839162
Showing 10 of 33 results.
Show More
-
Morgan GJ, Buxbaum JN, Kelly JW. Light Chain Stabilization: A Therapeutic Approach to Ameliorate AL Amyloidosis. Hemato. 2021 Dec; 2(4):645-659. PMID: 35757512; DOI: 10.3390/hemato2040042;
-
-
Yan NL, Santos-Martins D, Nair R, Chu A, Wilson IA, Johnson KA, Forli S, Morgan GJ, Petrassi HM, Kelly JW. Discovery of Potent Coumarin-Based Kinetic Stabilizers of Amyloidogenic Immunoglobulin Light Chains Using Structure-Based Design. J Med Chem. 2021 05 13; 64(9):6273-6299. PMID: 33939422; DOI: 10.1021/acs.jmedchem.1c00339;
-
Morgan GJ, Wall JS. The Process of Amyloid Formation due to Monoclonal Immunoglobulins. Hematol Oncol Clin North Am. 2020 12; 34(6):1041-1054. PMID: 33099422
-
Yan NL, Santos-Martins D, Rennella E, Sanchez BB, Chen JS, Kay LE, Wilson IA, Morgan GJ, Forli S, Kelly JW. Structural basis for the stabilization of amyloidogenic immunoglobulin light chains by hydantoins. Bioorg Med Chem Lett. 2020 08 15; 30(16):127356. PMID: 32631553; DOI: 10.1016/j.bmcl.2020.127356;
-
Rennella E, Morgan GJ, Yan N, Kelly JW, Kay LE. The Role of Protein Thermodynamics and Primary Structure in Fibrillogenesis of Variable Domains from Immunoglobulin Light Chains. J Am Chem Soc. 2019 08 28; 141(34):13562-13571. PMID: 31364359; DOI: 10.1021/jacs.9b05499;
-
Morgan GJ, Yan NL, Mortenson DE, Rennella E, Blundon JM, Gwin RM, Lin CY, Stanfield RL, Brown SJ, Rosen H, Spicer TP, Fernandez-Vega V, Merlini G, Kay LE, Wilson IA, Kelly JW. Stabilization of amyloidogenic immunoglobulin light chains by small molecules. Proc Natl Acad Sci U S A. 2019 04 23; 116(17):8360-8369. PMID: 30971495; DOI: 10.1073/pnas.1817567116;
-
Rennella E, Morgan GJ, Kelly JW, Kay LE. Role of domain interactions in the aggregation of full-length immunoglobulin light chains. Proc Natl Acad Sci U S A. 2019 01 15; 116(3):854-863. PMID: 30598439; DOI: 10.1073/pnas.1817538116;
-
Buxbaum JN, Morgan GJ. Summary: FASEB Science Research Conference on Protein Aggregation in Health and Disease. FASEB J. 2018 03; 32(3):1125-1129. PMID: 29521540; DOI: 10.1096/fj.201701266;
-
Morgan GJ, Usher GA, Kelly JW. Incomplete Refolding of Antibody Light Chains to Non-Native, Protease-Sensitive Conformations Leads to Aggregation: A Mechanism of Amyloidogenesis in Patients? Biochemistry. 2017 Dec 19; 56(50):6597-6614. PMID: 29200282; DOI: 10.1021/acs.biochem.7b00579;
-
Morgan GJ, Burkhardt DH, Kelly JW, Powers ET. Translation efficiency is maintained at elevated temperature in Escherichia coli. J Biol Chem. 2018 01 19; 293(3):777-793. PMID: 29183994; DOI: 10.1074/jbc.RA117.000284;
-
Morgan GJ, Kenny D, Duke C, Walsh KP, Qureshi SA. Initial assessment of a novel delivery system (NuDEL™ ®) for the covered Cheatham-Platinum stent. Cardiol Young. 2017 Oct; 27(8):1465-1469. PMID: 28857726
-
Jin HY, Oda H, Chen P, Yang C, Zhou X, Kang SG, Valentine E, Kefauver JM, Liao L, Zhang Y, Gonzalez-Martin A, Shepherd J, Morgan GJ, Mondala TS, Head SR, Kim PH, Xiao N, Fu G, Liu WH, Han J, Williamson JR, Xiao C. Differential Sensitivity of Target Genes to Translational Repression by miR-17~92. PLoS Genet. 2017 02; 13(2):e1006623. PMID: 28241004; DOI: 10.1371/journal.pgen.1006623;
-
Morgan GJ, Kelly JW. The Kinetic Stability of a Full-Length Antibody Light Chain Dimer Determines whether Endoproteolysis Can Release Amyloidogenic Variable Domains. J Mol Biol. 2016 10 23; 428(21):4280-4297. PMID: 27569045; DOI: 10.1016/j.jmb.2016.08.021;
-
Cooley CB, Ryno LM, Plate L, Morgan GJ, Hulleman JD, Kelly JW, Wiseman RL. Unfolded protein response activation reduces secretion and extracellular aggregation of amyloidogenic immunoglobulin light chain. Proc Natl Acad Sci U S A. 2014 Sep 09; 111(36):13046-51. PMID: 25157167; DOI: 10.1073/pnas.1406050111;
-
Morgan GJ. Tools and Techniques in Biomolecular Science (Divan A, Royds J, eds.). CD spectroscopy. Oxford. 2013.
-
Paramore R, Morgan GJ, Davis PJ, Sharma CA, Hounslow A, Taler-Vercic A, Zerovnik E, Waltho JP, Cliff MJ, Staniforth RA. Mapping local structural perturbations in the native state of stefin B (cystatin B) under amyloid forming conditions. Front Mol Neurosci. 2012; 5:94. PMID: 23091450; DOI: 10.3389/fnmol.2012.00094;
-
Morgan GJ and Radford SE. protein folding and misfolding: Shining light by infrared spectroscopy (Fabian H, Naumann D, eds.). Linked landscapes and conformational conversions: How proteins fold and misfold. Springer. 2012.
-
Pashley CL, Morgan GJ, Kalverda AP, Thompson GS, Kleanthous C, Radford SE. Conformational properties of the unfolded state of Im7 in nondenaturing conditions. J Mol Biol. 2012 Feb 17; 416(2):300-18. PMID: 22226836; DOI: 10.1016/j.jmb.2011.12.041;
-
Foit L, Morgan GJ, Kern MJ, Steimer LR, von Hacht AA, Titchmarsh J, Warriner SL, Radford SE, Bardwell JC. Optimizing protein stability in vivo. Mol Cell. 2009 Dec 11; 36(5):861-71. PMID: 20005848; DOI: 10.1016/j.molcel.2009.11.022;
-
Morgan GJ, Giannini S, Hounslow AM, Craven CJ, Zerovnik E, Turk V, Waltho JP, Staniforth RA. Exclusion of the native alpha-helix from the amyloid fibrils of a mixed alpha/beta protein. J Mol Biol. 2008 Jan 11; 375(2):487-98. PMID: 18021806; DOI: 10.1016/j.jmb.2007.10.033;
-
Jenko Kokalj S, Guncar G, Stern I, Morgan G, Rabzelj S, Kenig M, Staniforth RA, Waltho JP, Zerovnik E, Turk D. Essential role of proline isomerization in stefin B tetramer formation. J Mol Biol. 2007 Mar 09; 366(5):1569-79. PMID: 17217964; DOI: 10.1016/j.jmb.2006.12.025;
-
Halliwell CM, Morgan G, Ou CP, Cass AE. Introduction of a (poly)histidine tag in L-lactate dehydrogenase produces a mixture of active and inactive molecules. Anal Biochem. 2001 Aug 15; 295(2):257-61. PMID: 11488630; DOI: 10.1006/abio.2001.5182;
This graph shows the total number of publications by year, by first, middle/unknown,
or last author.
| Year | Publications |
|---|
| 2001 | 1 |
| 2006 | 1 |
| 2007 | 1 |
| 2009 | 1 |
| 2011 | 1 |
| 2012 | 2 |
| 2013 | 1 |
| 2014 | 1 |
| 2016 | 1 |
| 2017 | 4 |
| 2018 | 2 |
| 2019 | 2 |
| 2020 | 2 |
| 2021 | 4 |
| 2022 | 1 |
| 2023 | 3 |
| 2024 | 5 |